Phase I/II trial of formoterol fumarate combined with megestrol acetate in cachectic patients with advanced malignancy

Supportive Care in Cancer

Volumn 22, Issue 5, 2014, Pages 1269-1275

  Greig, C A ^a   Johns, N ^a   Gray, C ^a   MacDonald, A ^a   Stephens, N A ^a   Skipworth, R J E ^a   Fallon, M ^a   Wall, L ^b   Fox, G M ^c   Fearon, K C H ^a,d  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c Acacia Pharma Ltd   (United Kingdom)

^d ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

Adrenergic beta 2 receptor agonists; Cachexia; Megestrol; Neoplasms

Indexed keywords

FORMOTEROL FUMARATE; MEGESTROL ACETATE;

ADVANCED CANCER; AGED; APPETITE; ARTICLE; CACHEXIA; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; EVENING DOSAGE; FEMALE; HAND GRIP; HUMAN; MALE; MORNING DOSAGE; MUSCLE ATROPHY; MUSCLE FUNCTION; MUSCLE MASS; MUSCLE STRENGTH; PERIPHERAL EDEMA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHYSICAL ACTIVITY; PILOT STUDY; PRIORITY JOURNAL; QUADRICEPS FEMORIS MUSCLE; QUALITY OF LIFE; SCORING SYSTEM; STRENGTH; SUPRAVENTRICULAR TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; WEIGHT REDUCTION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; AGED; ANOREXIA; ANTHROPOMETRY; APPETITE STIMULANTS; CACHEXIA; COMBINED MODALITY THERAPY; ETHANOLAMINES; FEMALE; HUMANS; MALE; MEGESTROL; MEGESTROL ACETATE; MIDDLE AGED; NEOPLASMS; WEIGHT LOSS;

EID: 84897544651     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-013-2081-3     Document Type: Article

References (26)

1. Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12:489-495
2. Busquets S, Serpe R, Sirisi S, Toledo M, Coutinho J, Martinez R, Orpi M, Lopez-Soriano FJ, Argiles JM (2010) Megestrol acetate: its impact on muscle protein metabolism supports its use in cancer cachexia. Clin Nutr 29:733-737
3. Berenstein EG, Ortiz Z (2005) Megestrol acetate for the treatment of anorexia-cachexia syndrome. Cochrane Database Syst Rev CD004310
4. Beller E, TattersallM, Lumley T et al (1997) Improved quality of life with megestrol acetate in patients with endocrine-insensitive advanced cancer: a randomized placebo-controlled trial. Australasian Megestrol Acetate Cooperative Study Group. Ann Oncol 8:277-283 (Pubitemid 27153495)
5. Erkurt E, Erkisi M, Tunali C (2000) Supportive treatment in weight-losing cancer patients due to the additive adverse effects of radiation treatment and/or chemotherapy. J Exp Clin Cancer Res 19:431-439 (Pubitemid 32209840)
6. Skura CL, Fowler EG, Wetzel GT, Graves M, Spencer MJ (2008) Albuterol increases lean body mass in ambulatory boys with Duchenne or Becker muscular dystrophy. Neurology 70:137-143
7. Maltin CA, Delday MI, Watson JS, Heys SD, Nevison IM, Ritchie IK, Gibson PH (1993) Clenbuterol, a beta-adrenoceptor agonist, increases relative muscle strength in orthopaedic patients. Clin Sci (Lond) 84:651-654 (Pubitemid 23171175)
8. Martineau L, HoranMA, Rothwell NJ, Little RA (1992) Salbutamol, a beta 2-adrenoceptor agonist, increases skeletal muscle strength in young men. Clin Sci (Lond) 83:615-621
9. Argiles JM, Lopez-Soriano FJ, Busquets S (2007) Emerging drugs for cancer cachexia. Expert Opin Emerg Drugs 12:555-570 (Pubitemid 350189124)
10. Borger P, Hoekstra Y, EsselinkMT, Postma DS, Zaagsma J, Vellenga E, Kauffman HF (1998) Beta-adrenoceptor-mediated inhibition of IFN-gamma, IL-3, and GM-CSF mRNA accumulation in activated human T lymphocytes is solely mediated by the beta2-adrenoceptor subtype. Am J Respir Cell Mol Biol 19:400-407 (Pubitemid 128354209)
11. Yoshimura T, Kurita C, Nagao T et al (1997) Inhibition of tumour necrosis factor-alpha and interleukin-1-beta production by beta-adrenoceptor agonists from lipopolysaccharide-stimulated human peripheral blood mononuclear cells. Pharmacology 54:144-152 (Pubitemid 27136077)
12. Busquets S, FiguerasMT, Fuster G, Almendro V, Moore-Carrasco R, Ametler E, Argiles JM, Lopez-Soriano FJ (2004) Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res 64:6725-6731 (Pubitemid 39297935)
13. Ryall JG, SillenceMN, Lynch GS (2006) Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Br J Pharmacol 147: 587-595
14. Gray C, MacGillivray TJ, Eeley C, Stephens NA, Beggs I, Fearon KC, Greig CA (2011) Magnetic resonance imaging with k-means clustering objectively measures whole muscle volume compartments in sarcopenia/cancer cachexia. Clin Nutr 30(1):106-111
15. Lieffers JR, Mourtzakis M, Hall KD, McCargar LJ, Prado CM, BaracosVE (2009) Aviscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumour mass to whole-body energy demands. Am J Clin Nutr 89:1173-1179
16. Fearon KC, Voss AC, Hustead DS, Cancer Cachexa Study Group (2006) Definition of cancer cachexia: effect of weight loss, reduced food intake and systemic inflammation on functional status and prognosis. Am J Clin Nutr 83:1345-1350 (Pubitemid 44713065)
17. Jones DA, Rutherford OM (1987) Human muscle strength training: the effects of three different regimens and the nature of the resultant changes. J Physiol 391:1-11 (Pubitemid 17161425)
18. Sipila S, Suominen H (1995) Effects of strength and endurance training on thigh and leg muscle mass and composition in elderly women. J Appl Physiol 78:334-340
19. Baker DJ, Constantin-Teodosiu D, Jones SW, Timmons JA, Greenhaff PL (2006) Chronic treatment with the beta(2)- adrenoceptor agonist prodrug BRL-47672 impairs rat skeletalmuscle function by inducing a comprehensive shift to a faster muscle phenotype. J Pharmacol Exp Ther 319:439-446 (Pubitemid 44462679)
20. Lambert CP, Sullivan DH, Freeling SA, Lindquist DM, Evans WJ (2002) Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial. J Clin Endocrinol Metab 87:2100-2106 (Pubitemid 34521495)
21. Geller J, Albert J, Yen SS (1978) Treatment of advanced cancer of prostate with megestrol acetate. Urology 12:537-541 (Pubitemid 9049733)
22. Skipworth RJ, Moses AG, Sangster K, Sturgeon CM, Voss AC, Fallon MT, Anderson RA, Ross JA, Fearon KC (2011) Interaction of gonadal status with systemic inflammation and opioid use in determining nutritional status and prognosis in advanced pancreatic cancer. Support Care Cancer 19(3):391-401
23. Simons JP, Schols AM, Hoefnagels JM, Westerterp KR, ten Velde GP, Wouters EF (1998) Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial. Cancer 82:553-560 (Pubitemid 28112995)
24. MuscaritoliM, Anker SD, Argiles J et al (2010) Consensus definition of sarcopenia, cachexia and pre-cachexia: joint document elaborated by Special Interest Groups (SIG) "cachexia-anorexia in chronic wasting diseases" and "nutrition in geriatrics". Clin Nutr 29:154-159
25. Simons JP, Aaronson NK, Vansteenkiste JF et al (1996) Effects of medroxyprogesterone acetate on appetite, weight, and quality of life in advanced-stage non-hormone-sensitive cancer: a placebo-controlled multicenter study. J Clin Oncol 14:1077 - 1084
26. Choo JJ, Horan MA, Little RA, Rothwell NJ (1990) Effects of the beta 2-adrenoceptor agonist, clenbuterol, on muscle atrophy due to food deprivation in the rat. Metabolism 39:647-650 (Pubitemid 20184538)